Src kinase activity has been implicated in promoting key oncogenic mechanisms such as cell proliferation, adhesion, invasion, and resistance to apoptosis.[4, 5] In the present study, we have shown that dasatinib, an inhibitor of SFK, interacts synergistically with JSI-124, an agent known to inhibit STAT3/JAK pathways that are involved in glioma growth and survival. Here, STAT3 is linked to glioma.